You are here: Industry Insights > Emgality

News List

Lilly plans head-to-head migraine study comparing Emgality with Nurtec ODT pharmatimes
June 18, 2021
Eli Lilly is planning to conduct a head-to-head study comparing its calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) Emgality with Biohaven Pharmaceuticals’ Nurtec for the preventative treatment of migraine.
Four medicines accepted for use by NHS Scotland pharmatimes
April 13, 2021
The Scottish Medicines Consortium (SMC) has approved NHS funding for four new medicines, including treatments for multiple myeloma and severe migraine in its April 2020 decisions.
NICE recommends Lilly’s migraine med Emgality pharmatimes
November 20, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Emgality as a preventative treatment for migraine in adults with episodic and chronic migraine.
Lilly Announces Positive Results for Emgality from CONQUER Study americanpharmaceuticalreview
August 07, 2019
Eli Lilly and Company has announced Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of ...
Emgality maker Lilly courts payers with new migraine ER data fiercepharma
July 13, 2019
Sales of Eli Lilly’s migraine and cluster headache med Emgality have lagged behind competitors from Amgen and Novartis and Teva Pharmaceutical. And in its push to bring payers on board, Lilly is deploying a full-court press with some new patient data.
FDA Approves Emgality (galcanezumab-gnlm) for the Treatment of Episodic Cluster Headache drugs
June 06, 2019
FDA Approves Emgality (galcanezumab-gnlm) for the Treatment of Episodic Cluster Headache.
FDA ‘yes’ for Emgality in cluster headache pharmatimes
June 05, 2019
The US Food and Drug Administration (FDA) has announced the approval of the first treatment for episodic cluster headache that reduces the frequency of attacks, Eli Lilly’s Emgality (galcanezumab-gnlm).
Lilly asks migraine patients to use their imaginations in first DTC push for Emgality fiercepharma
February 18, 2019
Eli Lilly’s first effort for migraine drug Emgality had a personal connection for the director of the TV commercial.
European Commission approves Lilly's Emgality for migraine pharmatimes
November 22, 2018
Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.
FDA Approves Lilly’s Emgality Using Lonza’s Factor C Assay contractpharma
November 12, 2018
Becomes first FDA approved drug using this method instead of traditional LAL

Previous page 1 2 Next page